Efficacy and Safety of Elinzanetant in Vasomotor Symptoms in Menopause

This segment delves into findings from the OASIS-1, -2, and -3 trials evaluating elinzanetant. The data demonstrate robust efficacy in reducing both frequency and intensity of vasomotor symptoms (VMS) while maintaining favorable tolerability.

Safety outcomes show minimal hepatic impact and no hormone-related adverse events, supporting its use as a nonhormonal alternative. Participants also reported improved sleep and overall well-being, suggesting systemic benefits beyond thermoregulation.

Panelists view these results as a pivotal validation of neurokinin modulation as a cornerstone of future menopause therapy, bridging efficacy, safety, and broader patient satisfaction.